CONCLUSION
The prevalence of FVL mutations in our study did not appear significantly affect abortion in primigravida. MTHFR C667T mutations prevalence were appeared significantly have a relation to abortion. There was no significant increase in the prevalence of combined thrombophilia (Factor V Leiden and MTHFR C677T). The association between combined thrombophilia and abortion did not involve prothrombin gene G20210A mutations in the patient group. No homozygosity gene mutation was detected in the factor V patient group. Heterozygotes were significantly increased in the patient group compared to homozygotes for each of the two gene mutations studied. There is an association between some types of thrombophilia and miscarriage, but the absolute risk is small and varies considerably among reports.
Disclosure of interests: No potential competing financial, personal, political, intellectual, or religious interests were reported by the authors.
Author contributions: DE designed the study and performed data collection and analysis. MR interpreted and supervised the Lab analysis results. NE and NH supervised the clinical examinations and US findings. DE wrote the manuscript.All authors were involved in the revision of the manuscript.
Details of ethics approval: The clinical research study was approved by the Institutional Review Board (IRB) of Alexandria university hospital on 16 May 2019 with reference number 0105983. Informed consent was obtained before participation from patients or patient guardians in the case of incompetent patients.
Funding: This research received no specific grant from any funding agency.